Navigation Links
Potential treatment option for severe emphysema under study

Emory University researchers are participating in a nationwide study to explore an investigational treatment for advanced widespread emphysema. The EASE (Exhale Airway Stents for Emphysema) Trial focuses on airway bypass, a minimally invasive procedure designed to reduce excessive lung inflation and shortness of breath typical complications of emphysema - by making new pathways for trapped air to exit the lungs.

During the airway bypass procedure, new openings are created in the airway wall connecting the damaged lung tissue to the natural airway. These pathways are supported and kept open by several new drug-eluting stents.

"Emphysema permanently destroys lung function and there are currently limited treatment options for people with this devastating disease," says Rabih Bechara, MD, assistant professor and director of interventional pulmonology, Emory University School of Medicine. "This is an exciting study that could offer substantial relief to participants, and eventually possibly to the millions who suffer from the effects of emphysema."

Emphysema, usually caused by chronic tobacco smoking, is a persistent, progressive and irreversible lung disease characterized by shortness of breath and the destruction of lung tissue. Over time, the tiny air sacs in the lungs, or alveoli, are damaged and lose their elasticity.

This loss of the lungs' natural elasticity and the collapse of airways in the lung combine to make exhalation ineffective, leaving emphysema sufferers with hyperinflation because they are unable to get air out of their lungs. Breathing becomes inefficient and patients have to work very hard to breathe making normal activities, such as walking, eating or even bathing, difficult. There is no cure and few treatment options are available for most patients.

"By creating new pathways for airflow with the airway bypass procedure, we hope to reduce hyperinflation and improve lung function," says Bechara, principal investigator of the study at Emory. "Currently, patients are often in poor physical condition, struggling with each breath so if we can help patients breathe easier it is likely to improve their quality of life."

Physicians commonly use bronchoscopes to examine the airways within the lungs. Participants in the trial are randomized two to one to an airway bypass or a control group. If randomized to the airway bypass group, physicians will first use a Doppler probe inserted through the bronchoscope to identify a site in the airway that is away from blood vessels. A special needle is then used to make a small opening and the stent is placed in the passageway to keep it open. The procedure involves placing up to six Exhale Drug-Eluting Stents manufactured by Broncus Technologies, Inc.

Although this procedure is still under clinical investigation, feasibility data suggest it may hold promise for patients with emphysema. Results from the open-label Exhale Drug-Eluting Stent feasibility study were published in the October 2007 issue of the Journal of Thoracic and Cardiovascular Surgery. Positive results included a statistically significant reduction in the amount of air trapped in the lungs and an improvement in breathing for patients at six months after the airway bypass procedure.


Contact: Jennifer Johnson
Emory University

Related medicine news :

1. How to Help Down Syndrome and Other Special Needs Children - Free Booklet and Parenting Course Available This Month From The Institutes for the Achievement of Human Potential
2. Vasculitis Foundation Integrates Education, Outreach and Technology in First-Ever Webinar on Potentially Life-Threatening Disease
3. A potential approach to treatment of hepatitis B virus infection
4. LegalView Warns Proton Pump Inhibitor Patients of Potential Bone Fracture Risk Associated with Drug
5. Measures to assess potential lung injury during ventilation inadequate
6. Malaria prevention reduces anemia and improves educational potential in Kenyan schoolchildren
7. PMC and County Announce Potential Capital Partners for Hospital
8. Announcement Outlines 36 Month Custom Deployment Contract With Potential Revenues Reaching $30 Million Dollars
9. Wake Forest researchers say popular fish contains potentially dangerous fatty acid combination
10. Study further defines potential role of fish-based fatty acids in resolving, preventing asthma
11. CIBC World Markets Equity Research Downgrades Target Price of BVF from $12.00 to a Staggering Low of $7.50 Based on Potential Incumbent Win in Proxy Battle
Post Your Comments:
(Date:6/27/2016)... ... June 27, 2016 , ... ... professionals, announced today its affiliation with Tennessee Counseling Association. This new ... network of the Tennessee Counseling Association, adding exclusive benefits and promotional offers. , ...
(Date:6/26/2016)... ... , ... On June 10-11, 2016, A Forever Recovery, a holistic treatment center ... Breakfast Table in Battle Creek, MI, where the rehabilitation facility is located. This annual ... the world’s leading providers of cereal and other breakfast foods. Its residents often refer ...
(Date:6/25/2016)... , ... June 25, 2016 , ... ... policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at ... on several important health care topics including advance care planning, healthcare costs and ...
(Date:6/25/2016)... Long Beach, CA (PRWEB) , ... June 25, 2016 , ... ... from UCLA with Magna Cum Laude and his M.D from the David Geffen School ... San Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set ... drug or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, ... traumatic event. , Trauma sufferers tend to feel a range of emotions, from depression, ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 23, 2016 Research and Markets ... Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic ... Coating, Parenteral) - Global Forecast to 2021" report ... The global pharmaceutical excipients market is projected to ... of 6.1% in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: ... 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) assay ... sepsis or septic shock. With this clearance, Roche is ... a fully integrated solution for sepsis risk assessment and ... with bacterial infection and PCT levels in blood can ...
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on ... today announced that patient enrollment in its ongoing ... Duchenne) has exceeded 50% of its 24-patient target. ... in the third quarter of 2016, and to ...
Breaking Medicine Technology: